Examples of using Tecfidera in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Tecfidera is a medicine that contains the active substance dimethyl fumarate.
Patients treated with Tecfidera may develop severe prolonged lymphopenia see section 4.8.
Tecfidera may affect your white blood cell counts,
It is not known whether the ingredients in Tecfidera pass into breast milk.
Approximately 1,056 patients have received more than 2 years of treatment with Tecfidera.
It is not known whether treatment with Tecfidera might reduce the effectiveness of some vaccines.
stop using Tecfidera.
Do not use Tecfidera if you are pregnant unless you have discussed this with your doctor.
Four per cent(4%) of patients treated with Tecfidera discontinued due to gastrointestinal events.
urinary adverse events was similar for Tecfidera and placebo-treated patients.
The symptoms described in these cases were consistent with the known adverse event profile of Tecfidera.
Upon treatment with Tecfidera, mean lymphocyte counts decreased over the first year with a subsequent plateau.
No studies have been performed evaluating the efficacy and safety of Tecfidera when switching patients from other disease modifying therapies to Tecfidera. .
There are no known therapeutic interventions to enhance elimination of Tecfidera nor is there a known antidote.
Patients with serious infections should not start treatment with Tecfidera until the infection(s) is resolved.
similar in patients treated with Tecfidera or placebo.
Tecfidera seems to work by stopping the body's defence system from damaging your brain and spinal cord.
During treatment with Tecfidera, simultaneous use of other fumaric acid derivatives(topical or systemic) should be avoided.
A complete blood count is recommended prior to initiating Tecfidera and regularly during treatment see Blood/laboratory tests above.
Changes in renal and hepatic laboratory tests have been seen in clinical trials in subjects treated with Tecfidera see section 4.8.